Clinical Trial

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Study acronym: VISTAS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Protocol Amendment History 56 amendments
This ClinicalTrials.gov record has been amended 56 times since 2020-12-09; most recent amendment 2026-02-02.
Status change: Recruiting → Active, Not Recruiting 2025-09-15
Status change: Not Yet Recruiting → Recruiting 2021-01-04
Trial Details
NCT Number NCT04663308
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Primary Sclerosing Cholangitis
Enrollment 182 participants
Start Date 2020-12-18
Primary Completion 2026-06 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-04